Chronic Co-Morbid Conditions in HIV+ U.S. Adults on Highly-Effective Anti-Retroviral Therapy (R01)

archived

Purpose. This FOA issued by National Institute of Nursing Research, National Institutes of Health, solicits Research Project Grant (R01) applications from institutions/organizations proposing mechanistic projects or interventions designed to understand or intervene in chronic co-morbid conditions common to HIV+ adults living in the U.S. who are treated with anti-retroviral therapy. These conditions may be a result of anti-retroviral therapy or the HIV disease process. These same kinds of conditions may also be common in older non-infected adults, but more information is needed on the natural history, including both biological and behavioral manifestations, and appropriate intervention when HIV+ adults are affected by conditions, such as cachexia, diabetes, kidney disease, neurological changes, cardiovascular disease or cancer. Since the advent of the protease inhibitors in 1996-1997, anti-retroviral treatment options have been evolving, including the customized combination ART. It is important to evaluate this progress and identify new opportunities for research associated with the use of anti-retroviral therapies and the association of co-morbidities of HIV+ individuals as they live through middle and old age. Research exploring these issues utilizing interdisciplinary and multidisciplinary research teams is strongly encouraged, as are research teams including underrepresented, minority, disabled, or women investigators. Mechanism of Support. This FOA will utilize the R01 grant mechanism and runs in parallel with a FOA of identical scientific scope, RFA-NR-10-002, that encourages applications under the R21 mechanism.

High